NPS RADAR provides health professionals with timely, independent evidence-based information on new drugs and medical tests and changes to listings on the Pharmaceutical Benefits Scheme.

NPS RADAR is print-published 3 times a year, in line with major updates to the Schedule of Pharmaceutical Benefits, so it is available around the time when new medicines can be prescribed or dispensed.

Our free NPS RADAR email alerts keep subscribers up to date with new drugs and medical tests as each new issue of NPS RADAR is released.

Latest issue

Editorial: RADAR is going digital

To meet the changing needs of health professionals who need current information at their fingertips, RADAR is going digital.

Brief item: New fixed-dose combination bronchodilators for COPD

From 1 December 2015 two new fixed-dose combination (FDC) bronchodilators are PBS listed for adults with COPD: eformoterol/aclidinium (Brimica Genuair) and olodaterol/tiotropium (Spiolto Respimat).

Brief item: Brinzolamide with brimonidine tartrate (Simbrinza): Restricted Benefit listing

From 1 December 2015 brinzolamide with brimonidine tartrate fixed-dose combination (Simbrinza) is listed on the PBS for adults with either open-angle glaucoma or ocular hypertension who are not achieving adequate control of intraocular pressure with monotherapy.

Brief item: Pharmacological therapies in Australia for type 2 diabetes

Guidelines recommend a stepwise approach to management of type 2 diabetes mellitus. This article summarises first-, second- and third-line options, and when to use insulin and fixed-dose combinations.